Status:
UNKNOWN
Evaluation of Vascular Structure in Elderly Using High-frequency Ultrasound and Construction of a Multimodal Risk Assessment System for Cardiovascular Diseases: a Multicenter Study
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
Chinese PLA General Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions:
Atherosclerosis
Stroke
Eligibility:
All Genders
60+ years
Brief Summary
Coronary heart disease(CHD), stroke, and hypertension are major diseases that seriously affect human health.Pathologic changes in the arteries involved in the above diseases mainly occur in the intima...
Eligibility Criteria
Inclusion
- Age ≥ 60 years
- All patients had original ultrasound images of bilateral carotid arteries with DICOM format and arteriosclerosis clinical and laboratory data
- Original data of CCTA or examination results in the baseline status are needed for CHD patients
- Original data of intracranial artery MRA or examination results in the baseline status are needed for patients with ischemic stroke.
Exclusion
- Age is \<60 years old
- Severe cardiac insufficiency, New York Heart Association(NYHA) class IV and (or) left ventricular ejection fraction \<30%
- Uncontrollable severe hypertension (systolic blood pressure≥ 180 mmHg or diastolic blood pressure≥ 110 mmHg) or uncontrollable severe diabetes mellitus, i.e., diabetes mellitus complicated with acute complications (including diabetic ketoacidosis and hypertonic hyperglycemic nonketosis coma), or acute hyperglycemic state (random blood glucose\> 16.7mmol/L and (or) blood ketone 1.0-3.0mmol/L) without acute complications
- Severe valvular disease (moderate regurgitation and / or stenosis in each valve)
- Various cardiomyopathy caused by hypertrophic cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy, myocardial amyloidosis
- Severe arrhythmia: persistent atrial fibrillation or atrial flutter, degree II 2 and above atrioventricular block, complete left bundle branch block
- Severe hepatic and renal insufficiency (glutamate transaminase and / or glutamine transaminase\> 3 times the upper limit of normal value, Blood creatinine\> 134 μmol/L or an estimated glomerular filtration rate of \<60ml/min/1.73m2)
- Severe chronic obstructive pulmonary disease or asthma
- Severe non-cardiovascular disease (malignant tumor, thyroid disease, infection, connective tissue disease)
- Mental retardation or mental disorders
- Life expectancy \<3 years due to various factors
- Refusal to sign informed consent
- Allergy to contrast agent should also be ruled out for patients undergoing CCTA for CHD.
Key Trial Info
Start Date :
February 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
8000 Patients enrolled
Trial Details
Trial ID
NCT06221618
Start Date
February 15 2024
End Date
December 31 2025
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mei Zhang
Jinan, Shandong, China